that the results of the experiment would indicate whether, in the case of courses of injections of Imferon given clinically, it was better always to inject the material into the same site or to use multiple sites. The second object was to see whether iron-dextran increased the incidence of tumours in tissues distant from the site of injection. In previous experiments a higher than expected incidence of such tumours had been encountered (Haddow, 1963 ; Langvad, 1964 was encountered in Group 1. In this group the first undoubted sarcoma appeared after 329 days and the animal had to be killed because of it on the 354th day. Altogether, 14 out of 22 rats of this group (64%) which came to post-mortem developed large sarcomata for which they had to be killed, the average time of killing being 501 days. As stated above, autolysis prevented post-mortem examination in the case of two rats ; both of these were considered on the basis of macroscopic examination to have sarcomata, but have been excluded from the results shown in Table L No sarcomata of microscopic dimensions and no benign tumours were found at the injection site in any of the remaining rats of this group. The lowest incidence of rapidly growing sarcomata for which rats had to be killed was encountered in Group 4 : only 3 out of 23 rats (I 3 %) developed such tumours and these were killed after an average of 574 days. However, when injection sites showing sarcomatkt of microscopic dimensions were taken into account the incidence was 7 out of 23 (30%); and when, in addition, rats bearing benign tumours at the injection site were also included, the total incidence of animals with injection-site tumours became 10 out of 23 (43%). It was not uncommon for multiple sites to be involved simultaneously by tumour formation. Another way, therefore, of assessing the results in Groups 1 and 4 is to compare the ratio of the numbers of tumours to the number of sites injected with iron-dextran (see final column of Table I ). It may be seen that in Group 1, 14 out of the 22 sites examined post-mortem developed tumours, i.e. 64% of the sites injected. In Group 4, 17 out of the 138 sites examined (i.e. 12.3%) had tumours. The 22 sites in Group 1 each received 6 times as many injections as the 138 sites in Group 4. Thus, the incidence of tumours at the injection site in the two groups was approximately proportional to the number of injections and to the total dose of iron-dextran introduced into the site.
In general, the results in Groups 2 and 3 were intermediate between those in Groups 1 and 4 with regard to (1) the incidence of large sarcomata for which rats had to be killed, (2) the time of appearance of the first sarcoma, (3) the average time of killing because of large sarcomata, (4) the incidence of microscopic sarcomata and of benign tumours at the injection site, and (5) the ratio of tumourous sites to sites injected. However, in some respects the tumorigenic response in Group 2 was less impressive than that in Group 3, which was surprising. In Group 3 for instance, tumours developed in 29 out of 96 sites examined (30-2%), whereas in Group 2, the corresponding figures were 11 out of 46 sites (23.9 Y).
It is undoubtedly difficult to obtain a clear picture of the results of the experiment. One of the main reasons for this arises from the difficulty of interpreting the lesions which were regarded by us as early sarcomata. It cannot, in our view, be seriously doubted that these were truly malignant in nature, but it is difficult to judge how quickly they would have become large and obvious tumours if the animals bearing them had been allowed to live longer.
Perhaps the most helpful way of looking at the results is to compare average survival (see Table I ) and the incidence of animals which developed no injectionsite tumours in the various groups. Only 8 rats of Group 1, which were examined post-mortem, had no tumour at the injection site. (Fig. 4 and 5) .
Apart from sarcomata and fibromata, two small adenomatous lesions were seen. Presumably these arose from mammary gland elements, though all the rats used in the experiment were males. Table  1I . An interesting variety of tumours, some benign and some malignant, were seen. The overall incidence of both benign and malignant tumours in the irondextran treated-rats (Groups 1-4) was closely similar to that in the untreated controls (Group 5). The data are insufficient for comment regarding possible differences in the types of tumour arising in treated and control animals. (Some of the tumours are illustrated in Fig. 6-13 ).
DISCUSSION
The fact that benign or malignant tumours arose at 71 out of 302 injection sites in 92 rats treated with iron-dextran indicates once again that the carcino-genicity of this material given in this way is of no low order. On the other hand, the results of the experiment throw no light on the importance of the presence of iron-overloading in the genesis of tumours at the site of injection of iron-dextran (Golberg and Smith, 1958 , 1960a , 1960b Baker, Golberg, Martin and Smith, 1961) . Each rat in Groups 1-4 received a total of 12 ml. of iron-dextran (600 mg. iron). On 
